Correction: Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma [0.03%]
对特瑞普利单抗联合化疗新辅助治疗可切除食管鳞癌II期研究TD-NICE的四年随访修正结果
Yajie Mao,Zhiyuan Gao,Yichen Sun et al.
Yajie Mao et al.
Published Erratum
BMC cancer. 2026 Aug 1;26(1):913. DOI:10.1186/s12885-026-16475-4 2026
Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF) [0.03%]
新诊断胶质母细胞瘤患者在放疗前和期间开始肿瘤治疗场的疗效和可行性：I/II期临床试验（PriCoTTF）A组可行性队列结果
Sied Kebir,Christoph Oster,Sandeep Sharma et al.
Sied Kebir et al.
Background: Tumor Treating Fields improve survival when started after chemoradiotherapy in newly diagnosed glioblastoma, but the safety and feasibility of initiating treatment before and during radiotherapy remain uncerta...
Clinical Trial
BMC cancer. 2026 Jul 27;26(1):912. DOI:10.1186/s12885-026-16613-y 2026
Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models [0.03%]
弗鲁奎替尼联合TAS-102有望成为一项颇具前景的治疗策略：人源肿瘤异种移植模型中的抗肿瘤活性研究
Takahito Hara,Megumi Morimoto,Masaaki Kakehi et al.
Takahito Hara et al.
Background: The combination of bevacizumab and TAS-102 has emerged as a treatment option for metastatic colorectal cancer (CRC). Bevacizumab is an anti-VEGF-A antibody, and TAS-102 is a cytotoxic nucleotide analog. Recent...
Correction: Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells [0.03%]
HDAC抑制后糖蛋白变化影响SW13细胞的致癌潜能纠正通知
McKale R Montgomery,Elizabeth E Hull
McKale R Montgomery
Published Erratum
BMC cancer. 2026 Jul 30;26(1):910. DOI:10.1186/s12885-026-16504-2 2026
Retraction Note: Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study [0.03%]
撤回 notice:流式细胞仪监测疾病相关 9-O-乙酰化唾液酸糖蛋白的表达与已知cd 抗原结合，作为急性淋巴细胞白血病儿童 mrд 的指标：一项为期两年的纵向随访研究
Suchandra Chowdhury,Suman Bandyopadhyay,Chandan Mandal et al.
Suchandra Chowdhury et al.
Rethinking cancer control in low- and middle-income countries: from workforce expansion to systems transformation [0.03%]
重新思考低收入和中等收入国家的癌症防治：从扩大卫生人力到重塑体系
D Cristina Stefan,Edward Christopher Dee,Frederic Ivan Leong Ting et al.
D Cristina Stefan et al.
Editorial expression of concern: NMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo [0.03%]
表达关注的编辑部意见：NMD-1198是一种新的微管结合剂，可降低人肝细胞癌（HCC）细胞中的HIF-1alpha和STAT3活性，并且可在体内抑制生长和血管生成
Christian Moser,Sven A Lang,Akira Mori et al.
Christian Moser et al.
Published Erratum
BMC cancer. 2026 Jul 26;26(1):899. DOI:10.1186/s12885-026-16503-3 2026
Editorial Expression of Concern: Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells [0.03%]
撤稿声明：姜黄素类似物WZ35通过ROS依赖性内质网应激及G2 / M期细胞周期停滞诱导人前列腺癌细胞死亡
Xiuhua Zhang,Minxiao Chen,Peng Zou et al.
Xiuhua Zhang et al.
Editorial Expression of Concern: Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation [0.03%]
表达关注声明：阿培利司通过ROS和MAPK激活抑制胆囊癌的发生和发展
Xueyan Cao,Yang Yang,Wei Zhou et al.
Xueyan Cao et al.
Evaluation of surgical approach and adjuvant therapy in uterine sarcomas: an 11-year population-based study [0.03%]
子宫肉瘤手术入路和辅助治疗的评价：一项基于人口的11年研究
Filip Herbst,Erik Holmberg,Louise Moberg et al.
Filip Herbst et al.
Background: Uterine sarcomas are rare and high-quality evidence regarding optimal treatment is limited and difficult to produce. Methods: ...